Clinical Trials Logo

Pterygium clinical trials

View clinical trials related to Pterygium.

Filter by:

NCT ID: NCT06402643 Recruiting - Pterygium Clinical Trials

Comparison of Recurrence Between Mini-SLET and Limbal-Conjunctival Autograft Techniques in Primary Pterygium

Start date: June 22, 2024
Phase: N/A
Study type: Interventional

The surgical treatment options for pterygium, an abnormal growth on the eye's frontal surface can be treated with several surgical techniques. The rates of pterygium coming back varies depending on the surgical technique employed and other factors related to the patient and surgery. The objective of this study is to assess the efficacy and safety of incorporating a single amniotic membrane with stem cells in the treatment of primary pterygium, aiming to enhance surgical outcomes and minimize recurrence rates.

NCT ID: NCT06200727 Active, not recruiting - Glaucoma Clinical Trials

Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, corneal ulcer, and patients undergoing trabeculectomy for glaucoma. The main question aims to answer is PRF's effectiveness in ocular surface and fundus diseases. Participants will be divided into 2 groups, the experimental group will be treated with PRF and the control group will be treated with conventional surgery, with a 12-month postoperative follow-up to determine the role of PRF on wound healing in ophthalmic diseases.

NCT ID: NCT06042296 Not yet recruiting - Pterygium Clinical Trials

Expression of CD44, PCNA and E-cadherin in Pterygium Tissue

Start date: October 2023
Phase:
Study type: Observational [Patient Registry]

Purpose: Pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. Its pathogenesis remains unclear. In severe cases, it may extend into the central cornea, inducing irregular corneal astigmatism and causing loss of vision. CD44( phagocytic glycoprotein-1 ) is involved in the organization of certain cellular processes, for instance, cell adhesion, division, and migration, by binding with its main ligand, hyaluronic acid. Proliferating cell nuclear antigen (PCNA) is a proliferation marker in the nucleus. E-cadherin is a calcium-dependent transmembrane glycoprotein that plays a significant role in the protection of tissue integrity and cell-to-cell adhesion. This study aimed to determine the role of CD44, proliferating cell nuclear antigen (PCNA), and E-cadherin in pterygium formation and recurrence.

NCT ID: NCT05978687 Recruiting - Pterygium Clinical Trials

The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision

LIDPTER
Start date: September 1, 2023
Phase: Phase 4
Study type: Interventional

In pterygium excision procedures, the subconjunctival injection of xylocain is regarded as an uncomfortable and painful step in the procedure. While already being studied in other ophthalmic procedures such as glaucoma surgery (7), application of topical lidocaine gel is likely to minimize pain. The gel has a longer surface contact time due to its consistency, providing not only a longer anesthetic effect, but protecting the corneal surface against desiccation, when compared to eye drops. The investigators hypothesize that Ophtesic 2% lidocaine gel is as effective as an anesthetic in pterygium excision as subconjunctival injection, while providing more comfort during surgery and less corneal dryness afterwards. Our goal is to compare both the anesthetic and corneal surface effect of topical 2% lidocaine gel to subconjunctival injection of xylocaine 2% solution with 0.125 epinephrine in pterygium surgery: - Compare the patients pain during and after surgery - Compare corneal dryness after surgery. - Evaluate possible secondary events

NCT ID: NCT05812508 Not yet recruiting - Corneal Topography Clinical Trials

Comparison Between Bare Scleral Technique and Conjunctival Auto-graft on Corneal Topography After Pterygium Surgery

Start date: April 20, 2023
Phase:
Study type: Observational [Patient Registry]

Aim of the work: To study the corneal topographic pattern changes in patients who have pterygium excision by two surgical techniques (bare sclera, conjunctival autograft).

NCT ID: NCT05794204 Active, not recruiting - Pterygium Clinical Trials

RMP-A03 Ocular Suspension in Patients With Pterygium

Start date: June 9, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the safety and efficacy of an ocular medication on the treatment of pterygium.

NCT ID: NCT05627947 Completed - Pterygium Clinical Trials

Comparison Between Topical Mitomycin C and Cyclosporine

Start date: January 1, 2021
Phase: Phase 1
Study type: Interventional

Pterygium is a disease associated with proliferation of the fibrovascular tissues of the conjunctiva into the cornea and is related to factors such as ultraviolet light exposure, chronic stimulation, inflammation, climate, and genetics.

NCT ID: NCT05456425 Recruiting - Pterygium Clinical Trials

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Start date: June 30, 2022
Phase: Phase 3
Study type: Interventional

The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.

NCT ID: NCT05362253 Completed - Recurrent Pterygium Clinical Trials

Micro-Conjunctival Autografting Combined With Amniotic Membrane Transplantation Treating Recurrent Pterygium Trial

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

To observe the effect of micro-conjunctival autografting combined with amniotic membrane transplantation on the postoperative recurrence, complications and ocular surface symptoms among patients with recurrent pterygium.

NCT ID: NCT05314673 Completed - Pterygium Clinical Trials

Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients

Start date: January 1, 2019
Phase: Phase 4
Study type: Interventional

Purpose: To assess the efficacy and safety of a single preoperative intra-lesional bevacizumab injection in primary pterygium. Methods: The investigators conducted a randomized controlled interventional study from January 2019 to December 2020. The study included a total of 60 patients (60 eyes) with primary pterygium. The investigators defined two groups of 30 patients each. Group A received an intralesional injection of bevacizumab (Avastin), one month before surgery (lesion excision and conjunctival autograft). Group B (control) had only the surgical treatment. Patients were followed up seven days (D7), one month (M1), three months (M3), and six months (M6) post-operatively. Pre-, per- and post-operatively, photographs of the lesions were taken, as well as a pathological examination. The main outcome measures were the change in functional discomfort following intralesional bevacizumab injection and pterygium recurrence. Recurrence was defined by fibrovascular tissue growth extending more than 1 mm across the limbus. Therapeutic success was defined as the absence of pterygium recurrence in M6.